MedTrace Logo

Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

NCT05269329 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-03-08

No results posted yet for this study

Summary

Study to assess the efficacy and safety of XC8, film-coated tablets, 10 mg in comparison with placebo in patients with dry non-productive cough against acute respiratory infections, and to determine the dosing regimen of XC8, film-coated tablets, 10 mg for treatment of dry non-productive cough against acute respiratory infections.

Conditions

  • Common Cold
  • Acute Respiratory Infection
  • Influenza, Human

Interventions

DRUG

XC8, film-coated tablets, 20 mg/day

20 mg/day (1 tablet twice a day)

DRUG

XC8, film-coated tablets, 40 mg/day

40 mg/day (2 tablets twice a day)

DRUG

XC8, film-coated tablets, 80 mg/day

80 mg/day (4 tablets twice a day)

DRUG

Placebo

1, 2, or 4 tablets twice a day

Sponsors & Collaborators

  • Valenta Pharm JSC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2021-10-26
Completion
2021-10-26

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05269329 on ClinicalTrials.gov